软组织肉瘤市场规模、份额和成长分析（按类型、诊断、治疗方法、最终用户和地区划分）—2026-2033年产业预测

预计到 2024 年，全球软组织肉瘤市场规模将达到 41.1 亿美元，到 2025 年将达到 44.5 亿美元，到 2033 年将达到 83.6 亿美元，预测期（2026-2033 年）的复合年增长率为 8.2%。

全球软组织肉瘤市场正经历快速成长，这主要得益于癌症发病率的上升、人们对罕见癌症疾病认识的提高以及创新治疗方法的蓬勃发展。包括磁振造影（MRI）和正子断层扫描（PET）在内的诊断技术的进步，促进了早期发现，从而改善了治疗方案。大型製药公司增加对标靶治疗（例如蛋白酪氨酸激酶抑制剂和免疫疗法）的投资，进一步推动了市场扩张。监管机构对加速药物核准和孤儿药认定的支持，促进了新型治疗方法的研发。然而，挑战依然存在，包括患者群体有限、治疗费用高昂以及早期诊断的复杂性。此外，软组织肉瘤的异质性也增加了临床试验的难度，而标准治疗的副作用可能会影响患者的治疗依从性，尤其是在缺乏专业医疗资源的欠发达地区。

全球软组织肉瘤市场驱动因素

全球软组织肉瘤市场成长的主要驱动力是全球各类软组织肉瘤发生率和盛行率的不断上升。诊断技术的进步和对该疾病认识的加深，使得更多病例得以发现，从而导致对有效治疗方法的需求日益增长。这种不断增长的需求涵盖了多种治疗方法，包括手术、放射线治疗、化疗和创新标靶治疗。随着人们对软组织肉瘤的认识和检测率的持续提高，市场呈现出扩张的迹象，这反映出对能够满足软组织肉瘤患者多样化需求的先进治疗方案的迫切需求。

限制全球软组织肉瘤市场的因素

全球软组织肉瘤市场面临的主要障碍之一是疾病的罕见性和显着的异质性。软组织肉瘤包含多种组织学亚型，每种亚型都有独特的生物学行为和不同的治疗反应。这种罕见性使得进行大规模临床试验变得困难，并最终阻碍了有效治疗方法的研发。此外，亚型间的多样性也使得治疗方案的标准化变得复杂，并导致人们对该疾病的认识存在碎片化。这种情况阻碍了研究工作，并延缓了软组织肉瘤患者创新治疗方法的进展。

全球软组织肉瘤市场趋势

全球软组织肉瘤市场正经历着向标靶治疗和免疫疗法的兴起和应用的重大转变，这反映了肿瘤学领域的更广泛趋势。这些创新治疗方法透过特异性靶向癌细胞和活化免疫系统，显着改善了患者的治疗效果，与传统化疗相比，在提高疗效的同时，也可能降低毒性。随着医疗机构和研究人员更加重视个人化医疗，对这些先进治疗方法的需求也不断增长，从而推动了研发投入。这种转变不仅带来了更多更优的治疗选择，也促进了软组织肉瘤治疗中以病人为中心的理念。

目录

介绍

• 调查目标
• 市场定义和范围

调查方法

• 调查过程
• 二手资料和一手资料方法
• 市场规模估算方法

执行摘要

• 全球市场展望
• 市场主要亮点
• 细分市场概览
• 竞争格局概述

市场动态与展望

• 总体经济指标
• 驱动因素和机会
• 限制与挑战
• 供给面趋势
• 需求面趋势
• 波特的分析和影响

关键市场考察

• 关键成功因素
• 影响市场的因素
• 关键投资机会
• 生态系测绘
• 市场吸引力指数（2025）
• PESTEL 分析
• 价值链分析
• 定价分析
• 案例研究
• 监管环境
• 技术评估

全球软组织肉瘤市场规模（按类型及复合年增长率划分）（2026-2033 年）

• 血管肉瘤
• 上皮样肉瘤
• 胃肠道基质肿瘤（GIST）
• 其他的

全球软组织肉瘤市场规模（按诊断方法和复合年增长率划分）（2026-2033 年）

• 切片检查
• 超音波
• 磁振造影（MRI）
• 其他的

全球软组织肉瘤市场规模（按治疗方法和复合年增长率划分）（2026-2033 年）

• 标靶治疗
• 化疗
• 抗血管新生药物
• 放射线治疗
• 外科手术

全球软组织肉瘤市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 医院和诊所
• 癌症研究中心
• 其他的

全球软组织肉瘤市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Eli Lilly and Company（United States）
• Janssen Global Services, LLC（United States）
• Bayer AG（Germany）
• Bristol-Myers Squibb（BMS）（United States）
• Merck & Co., Inc.（United States）
• Eisai Co., Ltd.（Japan）
• Novartis International AG（Switzerland）
• Pfizer Inc.（United States）
• Roche Holding AG（Switzerland）
• AstraZeneca PLC（United Kingdom）
• Takeda Pharmaceutical Company Limited（Japan）
• Immunomedics（United States）
• Adaptimmune Therapeutics plc（United Kingdom）
• Blueprint Medicines（United States）
• Epizyme, Inc.（United States）
• Ipsen SA（France）
• Jazz Pharmaceuticals plc（Ireland）
• GE HealthCare（United States）
• Siemens Healthineers（Germany）
• Varian Medical Systems（United States）

结论与建议

Global Soft Tissue Sarcoma Market size was valued at USD 4.11 Billion in 2024 and is poised to grow from USD 4.45 Billion in 2025 to USD 8.36 Billion by 2033, growing at a CAGR of 8.2% during the forecast period (2026-2033).

The global market for soft tissue sarcoma is experiencing rapid growth driven by the rising incidence of cancer, heightened awareness of rare oncological conditions, and a robust pipeline of innovative therapies. Advancements in diagnostic technologies, including MRI and PET scans, facilitate early detection, leading to improved treatment options. Increased investment from major pharmaceutical companies in targeted therapies, such as tyrosine kinase inhibitors and immunotherapies, further propels market expansion. Regulatory support for faster drug approvals and orphan designations has encouraged the development of novel treatments. However, challenges persist, including a limited patient population, high treatment costs, and complexities in early diagnosis. Additionally, the heterogeneous nature of soft tissue sarcomas complicates clinical trials, while side effects from standard treatments may hinder adherence, especially in developing regions lacking specialized healthcare.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Soft Tissue Sarcoma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Soft Tissue Sarcoma Market Segments Analysis

Global Soft Tissue Sarcoma Market is segmented by Type, Diagnosis, Treatment, End User and region. Based on Type, the market is segmented into Angiosarcoma, Epithelioid Sarcoma, Gastrointestinal Stromal Tumor (GIST) and Others. Based on Diagnosis, the market is segmented into Biopsy, Ultrasound Scan, Magnetic Resonance Imaging (MRI) and Others. Based on Treatment, the market is segmented into Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy and Surgery. Based on End User, the market is segmented into Hospitals and Clinics, Cancer Research Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Soft Tissue Sarcoma Market

The Global Soft Tissue Sarcoma market is primarily driven by the rising incidence and prevalence of various forms of soft tissue sarcoma worldwide. Enhanced diagnostic techniques and a deeper understanding of the disease have contributed to the identification of more cases, consequently increasing the demand for effective treatment options. This growing need encompasses a range of therapeutic approaches, including surgical procedures, radiation therapy, chemotherapy, and innovative targeted therapies. As awareness and detection continue to improve, the market is poised for expansion, reflecting the urgency for advanced treatment solutions that cater to the diverse needs of patients diagnosed with soft tissue sarcoma.

Restraints in the Global Soft Tissue Sarcoma Market

One of the significant obstacles facing the global soft tissue sarcoma market is the uncommon nature and considerable heterogeneity of the disease. Soft tissue sarcoma comprises various histological subtypes, each displaying distinct biological behaviors and varying responses to treatment. This rarity presents challenges in organizing large-scale clinical trials and ultimately hinders the development of effective therapies. Furthermore, the diversity among subtypes complicates the standardization of treatment approaches, resulting in a fragmented understanding of the disease. This situation complicates research efforts and slows down advancements in innovative solutions for patients affected by soft tissue sarcoma.

Market Trends of the Global Soft Tissue Sarcoma Market

The Global Soft Tissue Sarcoma market is witnessing a significant shift towards the emergence and adoption of targeted therapies and immunotherapies, reflecting a broader trend in oncology. These innovative treatment modalities are transforming patient outcomes by specifically targeting cancer cells and leveraging the immune system, offering enhanced efficacy with potentially reduced toxicity compared to conventional chemotherapy. As healthcare providers and researchers focus on personalized medicine, the demand for these advanced therapies is increasing, driving investments in research and development. This shift not only fosters improved treatment options but also encourages a more patient-centric approach in the management of soft tissue sarcoma.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Technology Assessment

Global Soft Tissue Sarcoma Market Size by Type & CAGR (2026-2033)

• Market Overview
• Angiosarcoma
• Epithelioid Sarcoma
• Gastrointestinal Stromal Tumor (GIST)
• Others

Global Soft Tissue Sarcoma Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Biopsy
• Ultrasound Scan
• Magnetic Resonance Imaging (MRI)
• Others

Global Soft Tissue Sarcoma Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Targeted Therapy
• Chemotherapy
• Anti-Angiogenesis Drugs
• Radiation Therapy
• Surgery

Global Soft Tissue Sarcoma Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals and Clinics
• Cancer Research Centers
• Others

Global Soft Tissue Sarcoma Market Size & CAGR (2026-2033)

• North America (Type, Diagnosis, Treatment, End User)
  • US
  • Canada
• Europe (Type, Diagnosis, Treatment, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Diagnosis, Treatment, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Diagnosis, Treatment, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Diagnosis, Treatment, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Global Services, LLC (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (BMS) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immunomedics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adaptimmune Therapeutics plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Blueprint Medicines (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Epizyme, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE HealthCare (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Varian Medical Systems (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations